Grey Wolf Therapeutics

Gray Wolf Therapeutics is a UK-based biotechnology company focused on developing novel immuno-oncology drugs. Rather than targeting the immune system, Gray Wolf Therapeutics' approach directly alters tumor cells, illuminating them for the immune system to attack and destroy. The company targets ERAP proteases, key proteins in the antigen presentation pathway, to drive the modulation of the cancer-related antigen repertoire on tumor cells, thereby enhancing tumor visibility and broadening the scope of cancer immunotherapy.